RT Journal Article
SR Electronic
A1 Canavan, Neil
T1 Combination Biologic Therapy in Advanced Colorectal Cancer
JF MD Conference Express
YR 2008
FD SAGE Publications
VO 8
IS 4
SP 10
OP 10
DO 10.1177/155989770800800405
UL http://mdc.sagepub.com/content/8/4/10.abstract
AB The addition of a vascular endothelial growth factor antibody and an epidermal growth factor receptor inhibitor to chemotherapy had no benefit in advanced colorectal cancer. In fact, the combination had a significantly negative effect on progression-free survival. This article discusses the results of CAIRO2 [NCT00208546], a trial that was designed to investigate the effect of adding cetuximab to chemotherapy plus bevacizumab.